Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Mantle Cell Lymphoma International Prognostic Index (MIPI)

    Predicts survival in patients with mantle cell lymphoma.
    Favorite
    When to Use
    Pearls/Pitfalls
    Why Use

    Use in patients presenting with advanced stage mantle cell lymphoma, to help prognosticate and potentially determine therapy.

    • While most patients with advanced mantle cell lymphoma need to be treated soon after diagnosis, there is growing recognition of a small percentage of very low risk patients who may not need treatment for a much longer period.
    • If Ki-67 is available, it can be added to calculate the MIPIb or “biologic" score.

    The MIPI is more specific to mantle cell lymphoma than the International Prognostic Index (IPI).

    years
    0-1
    2-4
    U/L
    U/L
    × 10³ cells/µL
    %

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    • The MIPI categorizes patients into 3 risk groups: low, intermediate, or high.
    • Low-risk patients may be considered for close observation if there are no other indications for treatment.
    • However, both intermediate and high risk patients are treated with immunochemotherapy either alone or followed by autologous stem cell transplantation depending on many other patient factors such as age, comorbidities, side effect profiles, and patient preferences.

    Management

    There is diversity in clinical practice for the treatment of mantle cell lymphoma, with very few head-to-head studies of the various approaches. While we know a small number of patients with low-burden, low-risk disease may have an indolent course, it is difficult to identify those patients at diagnosis. Most patients will need treatment at diagnosis even though current treatment paradigms are not considered curative. The standard treatments are induction chemoimmunotherapy followed by autologous stem cell transplantation with or without maintenance.

    Content Contributors
    About the Creator
    Dr. Eva Hoster
    Are you Dr. Eva Hoster?
    Content Contributors